{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:46:57Z","timestamp":1792540017573,"version":"4.5.0"},"reference-count":24,"publisher":"Academy of Managed Care Pharmacy","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.18553\/jmcp.2023.29.11.1253","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T17:11:15Z","timestamp":1698426675000},"page":"1253-1259","source":"Crossref","is-referenced-by-count":9,"title":["Gene therapies for sickle cell disease: Effectiveness and value"],"prefix":"10.18553","volume":"29","author":[{"given":"Dmitriy","family":"Nikitin","sequence":"first","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca L.","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Thokala","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"McKenna","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Nhan","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rind","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009202"},{"issue":"108","key":"R3","volume":"21","author":"Huo J","year":"2018","journal-title":"Value Health"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7299-9_3"},{"issue":"5","key":"R6","first-page":"e24920","volume":"14","author":"Dick MH","year":"2022","journal-title":"Cureus"},{"key":"R7","unstructured":"Bradt P, Spackman E, Synnott P, Chapman R, Rind DM, Pearson S. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. Institute for Clinical and Economic Review, January 23, 2020. Accessed September 5, 2023. https:\/\/icer-review.org\/material\/sickle-cell-disease-draft-evidence-report\/"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1177\/0033354919881438"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30154-1"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005687"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745711"},{"key":"R12","unstructured":"Therapeutics CRISPR. FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia. Accessed August 25, 2023. https:\/\/crisprtx.com\/about-us\/press-releases-and-presentations\/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia"},{"key":"R13","unstructured":"Live CGT. No AdComm meeting for sickle cell therapy lovo-cel. Accessed August 25, 2023. https:\/\/www.cgtlive.com\/view\/no-adcomm-meeting-sickle-cell-therapy-lovo-cel"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117175"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162288"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146905"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109167"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26741"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001330"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.29159.bfs"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-528067"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107043250103"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.921.921"},{"key":"R28","unstructured":"Institute for Clinical and Economic Review. Adapted value assessment methods for high-impact \u201cSingle and Short-Term Therapies\u201d (SSTs). Accessed September 5, 2023. https:\/\/icer.org\/wp-content\/uploads\/2022\/12\/ICER_SST_FinalAdaptations_122122.pdf"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T15:41:32Z","timestamp":1700062892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2023.29.11.1253"}},"subtitle":["A Summary from the Institute for Clinical and Economic Review\u2019s California Technology Assessment Forum"],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.18553\/jmcp.2023.29.11.1253"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2023.29.11.1253","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}